Last reviewed · How we verify
TAK-285 Dose Escalation Cohorts — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TAK-285 Dose Escalation Cohorts (TAK-285 Dose Escalation Cohorts) — Millennium Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TAK-285 Dose Escalation Cohorts TARGET | TAK-285 Dose Escalation Cohorts | Millennium Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TAK-285 Dose Escalation Cohorts CI watch — RSS
- TAK-285 Dose Escalation Cohorts CI watch — Atom
- TAK-285 Dose Escalation Cohorts CI watch — JSON
- TAK-285 Dose Escalation Cohorts alone — RSS
Cite this brief
Drug Landscape (2026). TAK-285 Dose Escalation Cohorts — Competitive Intelligence Brief. https://druglandscape.com/ci/tak-285-dose-escalation-cohorts. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab